Byrd J C, Waselenko J K, Keating M, Rai K, Grever M R
Division of Hematology-Oncology, Walter Reed Army Medical Center, Washington, DC 20307, USA.
Semin Oncol. 2000 Oct;27(5):587-97.
Chronic lymphocytic leukemia (CLL) is one of the most common types of leukemia diagnosed in the Western Hemisphere. Introduction of the purine analogs has improved outcome for patients with CLL as measured by improvements in disease-free survival and has made it possible to attain a complete remission in a minority of patients with this disease. The therapeutic success with the purine analogs in CLL has led to preclinical and early clinical investigation of a variety of other therapeutic agents. This, combined with advances in the understanding the genetic and immunobiology of CLL, leaves hope that CLL may become a curable disease in this century.
慢性淋巴细胞白血病（CLL）是西半球诊断出的最常见白血病类型之一。嘌呤类似物的引入改善了CLL患者的预后，以无病生存期的改善来衡量，并且使得少数患有这种疾病的患者有可能实现完全缓解。嘌呤类似物在CLL治疗上的成功引发了对多种其他治疗药物的临床前和早期临床研究。这与在理解CLL的遗传和免疫生物学方面取得的进展相结合，让人看到希望，即在本世纪CLL可能成为一种可治愈的疾病。
